{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:06:15Z","timestamp":1789578375688,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC), the primary form of pancreatic cancer, has a very poor prognosis and urgently requires effective treatments. Chimeric antigen receptor T (CAR-T) cell therapy presents a potential treatment approach, yet it is often hindered by several factors, including an immunosuppressive microenvironment, limited tumour infiltration, modest anti-tumour activity and short-term T cell persistence. Here, we engineered an oncolytic herpes simplex virus expressing CXCL-11, IL-12 and a single-chain antibody against PD-1 (named oHSV30) to enhance CAR-T cell infiltration, cytotoxicity and persistence in the tumour microenvironment, thereby improving its therapeutic efficacy. In both immunocompetent and immunodeficient syngeneic PDAC models, we demonstrated that the combination of CAR-T cells with the intratumoural administration of oHSV30 significantly reduced tumour burden and prolonged the survival of tumour-bearing mice. Overall, our data suggest that oHSV30 can be a promising adjuvant for CAR-T therapy in PDAC.<\/jats:p>","DOI":"10.1038\/s41419-026-08695-0","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:16:20Z","timestamp":1775297780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Arming oncolytic herpes simplex virus with CXCL-11, IL-12 and a single-chain antibody against PD-1 to enhance CAR-T cell therapy in pancreatic ductal adenocarcinoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Xixi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yude","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6827-0318","authenticated-orcid":false,"given":"Nianchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"8695_CR1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","volume":"3","author":"AN Hosein","year":"2022","unstructured":"Hosein AN, Dougan SK, Aguirre AJ, Maitra A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat Cancer. 2022;3:272\u201386.","journal-title":"Nat Cancer"},{"key":"8695_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619:707\u201315.","journal-title":"Nature"},{"key":"8695_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"8695_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8:156.","journal-title":"Signal Transduct Target Ther"},{"key":"8695_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642\u201362.","journal-title":"Nat Rev Drug Discov"},{"key":"8695_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2022.198979","volume":"323","author":"N Zhang","year":"2023","unstructured":"Zhang N, Li J, Yu J, Wan Y, Zhang C, Zhang H, et al. Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR\/Cas9 system for colon cancer treatment. Virus Res. 2023;323:198979.","journal-title":"Virus Res"},{"key":"8695_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/cdd.2014.134","volume":"22","author":"S Tugues","year":"2015","unstructured":"Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, vom Berg J, et al. New insights into IL-12-mediated tumour suppression. Cell Death Differ. 2015;22:237\u201346.","journal-title":"Cell Death Differ"},{"key":"8695_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01626-4","volume":"9","author":"L Fang","year":"2023","unstructured":"Fang L, Yuan S, Wang M, Zhang C, Wang X, Li H, et al. Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-\u03b3 promotes CAR-T infiltration and proliferation in vivo to eradicate local and distal tumours. Cell Death Discov. 2023;9:328.","journal-title":"Cell Death Discov"},{"key":"8695_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax7992","volume":"12","author":"S Nakao","year":"2020","unstructured":"Nakao S, Arai Y, Tasaki M, Yamashita M, Murakami R, Kawase T, et al. Intratumoural expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Sci Transl Med. 2020;12:eaax7992.","journal-title":"Sci Transl Med"},{"key":"8695_CR10","doi-asserted-by":"crossref","unstructured":"Ge Y, Wang H, Ren J, Liu W, Chen L, Chen H, et al. Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumour effects with improved safety. J Immunother Cancer. 2020;8:e000710.","DOI":"10.1136\/jitc-2020-000710"},{"key":"8695_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020;6:eabd2712.","journal-title":"Sci Adv"},{"key":"8695_CR12","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nri3108","volume":"11","author":"LSK Walker","year":"2011","unstructured":"Walker LSK, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11:852\u201363.","journal-title":"Nat Rev Immunol"},{"key":"8695_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumour efficacy in vivo. Nat Biotechnol. 2018;36:847\u201356.","journal-title":"Nat Biotechnol"},{"key":"8695_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25:1408\u201314.","journal-title":"Nat Med"},{"key":"8695_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","volume":"4","author":"DA Reardon","year":"2016","unstructured":"Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res. 2016;4:124\u201335.","journal-title":"Cancer Immunol Res"},{"key":"8695_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","volume":"26","author":"JN Brudno","year":"2020","unstructured":"Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26:270\u201380.","journal-title":"Nat Med"},{"key":"8695_CR17","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010;116:3875\u201386.","journal-title":"Blood"},{"key":"8695_CR18","doi-asserted-by":"crossref","unstructured":"Maurice NJ, McElrath MJ, Andersen-Nissen E, Frahm N, Prlic M. CXCR3 enables recruitment and site-specific bystander activation of memory CD8+ T cells. Nat Commun. 2019;10:4987.","DOI":"10.1038\/s41467-019-12980-2"},{"key":"8695_CR19","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy: current perspectives and future directions. Cell. 2023;186:1652\u201369.","journal-title":"Cell"},{"key":"8695_CR20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200626120","volume":"120","author":"S D\u00f6tsch","year":"2023","unstructured":"D\u00f6tsch S, Svec M, Schober K, Hammel M, Wanisch A, G\u00f6kmen F, et al. Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression. Proc Natl Acad Sci USA. 2023;120:e2200626120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8695_CR21","doi-asserted-by":"crossref","unstructured":"Ju F, Luo Y, Lin C, Jia X, Xu Z, Tian R, et al. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoural immune response to control tumour and synergizes with CTLA-4 or TIM-3 blockade. J Immunother Cancer. 2022;12:e004762corr1.","DOI":"10.1136\/jitc-2022-004762corr1"},{"key":"8695_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","volume":"42","author":"S Kaczanowska","year":"2024","unstructured":"Kaczanowska S, Murty T, Alimadadi A, Contreras CF, Duault C, Subrahmanyam PB, et al. Immune determinants of CAR-T cell expansion in solid tumour patients receiving GD2 CAR-T cell therapy. Cancer Cell. 2024;42:35\u201351.e38.","journal-title":"Cancer Cell"},{"key":"8695_CR23","doi-asserted-by":"publisher","first-page":"6808","DOI":"10.1158\/1538-7445.AM2024-6808","volume":"84","author":"CV Ong","year":"2024","unstructured":"Ong CV, Kaczanowska S, Ju W, Cronk J, Ramakrishna S, Kaplan R. Abstract 6808: Investigating the role of CXCR3+ monocytes on CAR T cell function. Cancer Res. 2024;84:6808.","journal-title":"Cancer Res"},{"key":"8695_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21:47\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"8695_CR25","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","volume":"40","author":"NA Ullman","year":"2022","unstructured":"Ullman NA, Burchard PR, Dunne RF, Linehan DC. Immunologic strategies in pancreatic cancer: making cold tumours hot. J Clin Oncol. 2022;40:2789\u2013805.","journal-title":"J Clin Oncol"},{"key":"8695_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022;7:117.","journal-title":"Signal Transduct Target Ther"},{"key":"8695_CR27","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","volume":"18","author":"I Melero","year":"2021","unstructured":"Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol. 2021;18:558\u201376.","journal-title":"Nat Rev Clin Oncol"},{"key":"8695_CR28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","volume":"18","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination with cancer immunotherapy. Nat Rev Immunol. 2018;18:498\u2013513.","journal-title":"Nat Rev Immunol"},{"key":"8695_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn2231","volume":"14","author":"L Evgin","year":"2022","unstructured":"Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, et al. Oncolytic virus\u2013mediated expansion of dual-specific CAR T cells improves efficacy against solid tumours in mice. Sci Transl Med. 2022;14:eabn2231.","journal-title":"Sci Transl Med"},{"key":"8695_CR30","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/s44222-024-00231-z","volume":"2","author":"AO Omole","year":"2024","unstructured":"Omole AO, Zhao Z, Chang-Liao S, Affonso de Oliveira JF, Boone CE, Sutorus L, et al. Virus nanotechnology for intratumoural immunotherapy. Nat Rev Bioeng. 2024;2:916\u201329.","journal-title":"Nat Rev Bioeng"},{"key":"8695_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133\u201346.","journal-title":"Nat Rev Immunol"},{"key":"8695_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40115-1","volume":"14","author":"EHJ Lee","year":"2023","unstructured":"Lee EHJ, Murad JP, Christian L, Gibson J, Yamaguchi Y, Cullen C, et al. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. Nat Commun. 2023;14:4737.","journal-title":"Nat Commun"},{"key":"8695_CR33","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1038\/s41590-024-01961-3","volume":"25","author":"SA Weiss","year":"2024","unstructured":"Weiss SA, Huang AY, Fung ME, Martinez D, Chen ACY, LaSalle TJ, et al. Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control. Nat Immunol. 2024;25:1871\u201383.","journal-title":"Nat Immunol"},{"key":"8695_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47799-z","volume":"15","author":"I Andreu-Saumell","year":"2024","unstructured":"Andreu-Saumell I, Rodr\u00edguez-Garc\u00eda A, M\u00fchlgrabner V, Gim\u00e9nez-Alejandre M, Marzal B, Castellsagu\u00e9 J, et al. CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition. Nat Commun. 2024;15:3552.","journal-title":"Nat Commun"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08695-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08695-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08695-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:56:21Z","timestamp":1779094581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08695-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8695"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08695-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of North Sichuan Medical College (Approval No. 2023043) and were conducted in accordance with the relevant guidelines and regulations of the institution. The collection of peripheral blood samples from healthy donors was performed in compliance with applicable guidelines and regulations and was approved by the Ethics Committee of North Sichuan Medical College (Approval No. 2025004). Written informed consent was obtained from all volunteers who participated in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"455"}}